[1]OrganicLetters,2010,vol.12,p.1984-1987
[2]OrganicLetters,2007,vol.9,p.5525-5528
[3]JournalofMedicinalChemistry,1996,vol.39,p.2281-2284
[1]JournalofMedicinalChemistry,1999,vol.42,p.1053-1065
[1]JournalofMedicinalChemistry,1999,vol.42,p.1053-1065
[1]JournalofMedicinalChemistry,1999,vol.42,p.1053-1065
[1]JournalofMedicinalChemistry,1999,vol.42,p.1053-1065
[2]Patent:US6277862,2001,B1
Title: Giardina GA, et al. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412). J Med Chem. 1999 Mar 25;42(6):1053-65.
Title: Houghton LA, et al. Effect of the NK(3) receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans. Neurogastroenterol Motil. 2007 Sep;19(9):732-43.
Title: Dawson LA, et al. In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia. Neuropsychopharmacology. 2008 Jun;33(7):1642-52.